CBP-307
Ulcerative Colitis, Crohn's Disease
Phase 2Development Terminated (2022)
Key Facts
Indication
Ulcerative Colitis, Crohn's Disease
Phase
Phase 2
Status
Development Terminated (2022)
Company
About Zeria Pharmaceutical
Zeria Pharmaceutical is a mid-sized, established Japanese pharmaceutical company with a history spanning over 70 years. It has built a stable business foundation through a multi-pronged strategy involving in-house development, strategic licensing, and marketing of both prescription and consumer health products. The company's strategic direction focuses on strengthening its core gastroenterology franchise while expanding into new therapeutic areas like dermatology and pursuing growth in Asian markets.
View full company profile